Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
Article
Google Scholar
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
Article
CAS
Google Scholar
Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61(6):1132–8.
Article
Google Scholar
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17.
Article
Google Scholar
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17.
Article
Google Scholar
Kjolhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int. 2012;110(10):1501–6.
Article
Google Scholar
Puterman C, Bjoersdorff M, Amidi J, Anand A, Soller W, Jiborn T, et al. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. Scand J Urol. 2021;55(4):293–7.
Article
CAS
Google Scholar
Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635–42.
Article
Google Scholar
Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, et al. (68)Ga-PSMA-11 positron emission tomography/computed tomography for primary lymph node staging before radical prostatectomy: central review of imaging and comparison with histopathology of extended lymphadenectomy. Eur Urol Focus. 2021;7(2):288–93.
Article
Google Scholar
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.
Article
Google Scholar
Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61(8):1153–60.
Article
CAS
Google Scholar
Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A. Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05745-5.
Article
PubMed
Google Scholar
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61(4):527–32.
Article
CAS
Google Scholar
Hoberuck S, Lock S, Borkowetz A, Sommer U, Winzer R, Zophel K, et al. Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11(1):109.
Article
Google Scholar
Rahbar K, Afshar-Oromieh A, Bogemann M, Wagner S, Schafers M, Stegger L, et al. (18)F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45(8):1329–34.
Article
CAS
Google Scholar
Ross S. Q.Clear White paper. GE Healthcare; 2014.
Tragardh E, Minarik D, Brolin G, Bitzen U, Olsson B, Oddstig J. Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer. EJNMMI Phys. 2020;7(1):31.
Article
Google Scholar
Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v.10 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626–38.
Article
Google Scholar
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.
Article
CAS
Google Scholar
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61(3):480–7.
Article
Google Scholar
Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, et al. Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with d’amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol. 2020;203(2):338–43.
Article
Google Scholar
Moreira LF, Mussi TC, Cunha MLD, Filippi RZ, Baroni RH. Accuracy of (68)Ga-PSMA PET/CT for lymph node and bone primary staging in prostate cancer. Urol Oncol. 2022;40(3):104.e17-104.e21.
Article
CAS
Google Scholar
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.
Article
CAS
Google Scholar
Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, et al. Intraindividual comparison of (18)F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective. Proof Concept Study J Nucl Med. 2017;58(11):1805–10.
Article
CAS
Google Scholar
Meijer D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study. Eur Urol. 2021;80(2):234–42.
Article
Google Scholar
Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Kusters-Vandevelde HVN, Wijers CHW, et al. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05827-4.
Article
PubMed
Google Scholar
Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, et al. Diagnostic accuracy of (18)F-PSMA-1007 PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med. 2021;62(2):208–13.
Article
CAS
Google Scholar
Eiber M, Kroenke M, Wurzer A, Ulbrich L, Jooss L, Maurer T, et al. (18)F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2020;61(5):696–701.
Article
CAS
Google Scholar
Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by (18)F-or (68)Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61(5):735–42.
Article
CAS
Google Scholar
Rauscher I, Karimzadeh A, Schiller K, Horn T, D'Alessandria C, Franz C et al. Detection efficacy of (18)F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med; 2021.
Kroenke M, Schweiger L, Horn T, Haller B, Schwamborn K, Wurzer A, et al. Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263707.
Article
PubMed
Google Scholar
Rauscher I, Kronke M, Konig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51–7.
Article
CAS
Google Scholar
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.
Article
Google Scholar
Oddstig J, Leide Svegborn S, Almquist H, Bitzen U, Garpered S, Hedeer F, et al. Comparison of conventional and Si-photomultiplier-based PET systems for image quality and diagnostic performance. BMC Med Imaging. 2019;19(1):81.
Article
Google Scholar
Parvizi N, Franklin JM, McGowan DR, Teoh EJ, Bradley KM, Gleeson FV. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases? Eur J Radiol. 2015;84(10):1873–8.
Article
Google Scholar
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.
Article
Google Scholar
Alberts I, Hunermund JN, Sachpekidis C, Mingels C, Fech V, Bohn KP, et al. The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. Eur Radiol. 2021;31(10):8030–9.
Article
Google Scholar
Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, et al. (68)Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022;15(1): 101293.
Article
Google Scholar